Our Life Sciences & HealthTech team serves startups and high-growth companies, as well as investors, in all aspects of their operations – from formation to venture financing, IP protection, essential collaboration agreements, regulatory compliance and exits. We also represent serial acquirers in their investments in the sector.
We draw on our global top 5 venture capital practice (No. 1 across Europe, Pitchbook) and deep sector knowledge to help companies and investors transact across borders.
Venture financing guidance is table stakes. We are just as fluent in helping companies structure complex transactions, such as licensing agreements, reverse mergers, project financings and royalty financings. These deal structures provide critical capital and commercial opportunities to companies in a turbulent market. We combine all our transactional expertise with multi-dimensional regulatory support to ensure successful deal execution and investment strategies.
We act for more than 350 life sciences, healthtech and digital health companies and leading investors. We help companies scale through holistic guidance on strategic transactions, IP and regulatory considerations. In 2023, we helped these clients raise $2.5B in venture financing through 81 transactions in 7 countries.
We assist with drug and device development, manufacturing and commercialization agreements. We counsel innovators in all kinds of small-molecule drugs, biologics and diagnostics, including cancer testing and therapeutics, proteomics, RNA technology, gene sequencing and CRISPR gene editing technology.
We work with our clients to shape IP strategies for the long term – ensuring they are well-positioned to develop, defend and commercialize their most important assets. This includes advising startups, Fortune 500 companies, investors and venture funds on IP diligence and patent protection.
Serial acquirers and private equity firms turn to us to efficiently execute transactions, navigate the antitrust environment and enhance their overall M&A strategies. Our M&A and private equity team worked across 46 markets worldwide in 2023.
We have a record of helping life sciences companies prepare to go public, complete IPOs and operate as a public company, including establishing strong corporate governance.
In today’s challenging market, we are pioneering financing techniques for the sector. This includes purchasing and selling existing pharmaceutical royalty streams, synthetic royalties, and other types of royalty monetization and royalty-based financing deals. We also work with investors and companies to structure novel drug development project financing solutions for late-stage clinical trials.